Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
Sera Prognostics General Counsel Benjamin Jackson acquired additional company stock through an employee plan. On May 29, Jackson acquired 5,000 shares of Class A common stock at $1.84 per share under Sera Prognostics’ 2021 Employee Stock Purchase Plan for the purchase period from December 1, 2025 to May 29, 2026. Following this acquisition, he directly holds 163,935 shares. The transaction is classified as a grant or award-type acquisition and is exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating it is a routine, compensation-related purchase rather than a discretionary open-market trade.
Sera Prognostics, Inc.’s Chief Commercial Officer, Dyaarl Lee Anderson Jr., acquired 3,168 shares of Class A Common Stock at $1.84 per share. These shares were purchased through the company’s 2021 Employee Stock Purchase Plan for the purchase period from December 1, 2025 to May 29, 2026.
Following this transaction, he directly holds 82,737 shares of Class A Common Stock. The filing characterizes the event as a grant, award, or other acquisition exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating a routine employee share purchase rather than an open-market trade.
Sera Prognostics, Inc. reported a planned board transition, with director Jeff Elliott resigning effective June 4, 2026, coinciding with the company’s Annual Stockholders Meeting. His departure is described as not resulting from any disagreement over operations, policies or practices, and his current term was already set to expire at that meeting.
The board reduced its size to seven directors following his resignation and is in advanced discussions with highly qualified candidates to join, expecting to announce a new appointment in the near term. Elliott, who joined the board in March 2025, expressed continued confidence in Sera’s mission to improve maternal and neonatal health through its PreTRM Test and broader pregnancy diagnostics pipeline.
SERA proposed the sale of 6,765 shares of Class A Common stock via a Form 144 notice. The shares are described as restricted stock vesting under a registered plan with a vesting date of 02/06/2024 and the brokerage listed as Morgan Stanley Smith Barney LLC. The filing shows a numeric field $11,561.39 and a larger numeric field 38,190,966 in the same table; the excerpt does not attach explicit labels to those two figures.
SERA PROGNOSTICS, INC. officer Paul Kearney, Chief Data Officer, filed a Form 4 reporting no insider trading activity. The filing shows no reported purchases, sales, option exercises, gifts, tax withholdings, or other equity transactions, and no derivative positions listed for this period.
SERA PROGNOSTICS, INC. executive Harrison Robert Gardner, the Chief Information Officer, filed a Form 4 insider report. The provided data shows no reported purchases, sales, gifts, exercises, or other share transactions, and no derivative positions or holdings are listed in this filing.
SERA PROGNOSTICS, INC. filed a Form 4 for Chief Scientific Officer John J. Boniface. The filing shows no reported purchases, sales, gifts, exercises, or other insider transactions, with all transaction counts and share amounts listed as zero in the summary data.
Sera Prognostics reported another early-stage quarter with very limited revenue and ongoing losses while highlighting a strong cash position and cost-cutting plans. For the three months ended March 31, 2026, revenue was $14 thousand, down from $38 thousand, and net loss was $8.4 million, or $0.17 per share.
Total assets were $93.5 million, including $4.2 million in cash and equivalents and $82.6 million in marketable securities, with stockholders’ equity of $67.6 million. The company is refocusing from research to commercialization of its PreTRM test, cutting about 18% of its workforce and expecting roughly $1.3 million in severance costs and about $9.6 million in 2027 cost savings. Management believes existing liquidity can fund operations through 2029.
Sera Prognostics, Inc. reported first quarter 2026 results, showing it remains in an early commercial stage while emphasizing extended financial runway. Revenue was $14,000 versus $38,000 a year earlier, reflecting limited commercial adoption of its PreTRM test so far.
Total operating expenses were $9.4 million, with $3.0 million in research and development and $6.3 million in selling, general and administrative costs as the company invests in commercialization. Net loss was $8.4 million, or $0.17 per share, similar to the prior-year loss.
As of March 31, 2026, Sera held about $86.8 million in cash, cash equivalents and marketable securities and expects this to fund operations through 2029 after a business review that shifted spending from clinical work toward reimbursement-driven commercialization. The company highlighted new clinical evidence for its PreTRM test, growing clinician engagement, payer discussions across 15 states and progress toward CE marking in Europe.
Sera Prognostics reports amended Schedule 13G ownership by Whetstone Capital Advisors, LLC and David Atterbury. The filing states the Reporting Persons beneficially own 3,306,889 shares of Class A Common Stock, representing 8.6% of the class. The signature dates are 05/01/2026.